Market Chatter: Eli Lilly, Bayer Back US Campaign to Increase Drug Prices in Europe

MT Newswires Live06-24

Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported on Tuesday.

Referring to a trade investigation into Germany on spending on new drugs, Patrik Jonsson, president of Eli Lilly's international division, told the FT that the probe is drawing attention to a long-held industry view that Europe pays too little for patented medicines.

Stefan Oelrich, head of Bayer's pharmaceuticals division, compared Europe's reliance on lower US-funded drug prices to its dependence on American defense spending, referring to President Donald Trump's numerous calls for North Atlantic Treaty Organization members to increase defense spending, the FT reported.

Eli Lilly and Bayer did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment